Abstract:Background Surgical resection is often the preferred treatment for non-small cell lung cancer (NSCLC) patients. Predictive biomarkers after surgery can help monitoring and treating patients promptly, so as to improve the clinical outcome. In this study, we evaluated one potential candidate biomarker, the folate receptor-positive circulating tumor cell (FR + CTC), by investigating its prognostic and predictive significance in NSCLC patients who underwent surgery. Methods In this prospective, observational study, we enrolled NSCLC patients who were eligible to receive surgery. Prior to operation, peripheral blood was collected from each patient for an FR + CTC analysis. FR + CTCs were isolated by negative enrichment using immunomagnetic beads to deplete leukocytes and then quantitatively detected by a ligand-targeted polymerase chain reaction (PCR) method. These patients were then given standard care and were actively followed up for seven years. At the end of the follow-up period, the association between the FR + CTC level and the prognosis in these patients was evaluated. Results Overall, preoperative FR + CTC level was not significantly different among NSCLC patients with adenocarcinoma or non-adenocarcinoma subtypes ( P = 0.24). However, between patients with low- and high-risk pathological adenocarcinoma subtypes, the preoperative FR + CTC level was significantly different ( P = 0.028). Further, patients with lower preoperative FR + CTC level had longer relapse-free survival (RFS) and overall survival (OS) than those with higher preoperative FR + CTC level (RFS: not reached vs. 33.3 months, P = 0.018; OS: not reached vs. 72.0 months, P = 0.13). In a multivariate COX regression analysis, FR + CTC level (HR = 4.10; 95% CI, 1.23–13.64; P =0.022) and pathological stage (HR = 3.16; 95% CI, 1.79–10.14; P = 0.0011) were independent prognostic factors of RFS. Moreover, FR + CTC level together with adenocarcinoma subtypes provided additional information on risk for disease recurrence compared with FR + CTC or adenocarcinoma subtype alone. Conclusion Our study demonstrated that the preoperative FR + CTC level was a potential predictor for the prognosis of NSCLC patients underwent surgery. Further, when preoperative FR + CTC level is considered together with primary tumor proliferation characteristics, its prognostic value supplements that of these conventional pathological features.

Blood Telomerase Activity and Its Correlativity with Non-Small Cell Lung Carcinoma

Correlation of Pathological Types and Clinical Stages of NSCLC with the Blood Telomerase Activity

Study of Telomerase Activity in Pleural Lavage Fluid Specimens in Patients with Non-Small-cell Lung Cancer and Its Clinical Significance

The Detectin of Telomerase Activity in Non-Small Cell Lung Cancer

The Expression of Telomerase Activity in Patients with Non-Small Cell Lung Cancer

Telomerase Activity of Fibrobronchoscopic Brushing Cells in Non-Small Cell Lung Cancer

[Relationship among Telomerase Activity, Telomerase RNA and Telomerase Catalytic Subunit Gene Expression and Their Significance in Non Small-Cell Lung Cancer].

Expression Of Telomeric Repeat Binding Factor 1 Protein In Nonsmall Cell Lung Cancer With Human Telomerase Reverse Transcriptase Positive

[Serum Levels of Endostatin and VEGF in Non-Small Cell Lung Cancer Patients and the Relationship with the Clinical Pathophysiological Characteristics].

Discriminating Association of a Common Telomerase Reverse Transcriptase Promoter Polymorphism with Telomere Parameters in Non-Small Cell Lung Cancer with or Without Epidermal Growth Factor Receptor Mutation.

Abnormal Expression and Clinical Significance of Telomeric Repeat Binding Factor 1 and Tankyrase 1 in Non-small Cell Lung Cancer

Use of Telomere Length in Peripheral Leukocytes to Predict Risk of Recurrence in Patients with Early-Stage Non-Small Cell Lung Cancer after Curative Resection.

Expression of Telomeric Repeat Binding Factor 1 in Non-Small Cell Lung Cancer.

Expression of Catalytic Subunit Gene Htert of Telomerase and Its Clinical Significance in Non-small Cell Lung Cancer

Quantification Of Alternative Splicing Variants Of Human Telomerase Reverse Transcriptase And Correlations With Telomerase Activity In Lung Cancer

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

Detection of telomerase activity in breast carcinoma

Role of Serum Tumor Markers in Prognosis of Operable Non-small Cell Lung Cancer Patients

Telomerase activity in Indian patients with carcinomas of the aerodigestive tract

Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients

Relation between peripheral blood active circulating tumor cell and clinical characteristics of non-small cell lung cancer